Cernilton

Cernilton is a drug for the treatment of prostate diseases. It was developed in Sweden and is marketed under the Centyrell AB brand. The international name of the drug is cernilton.

One of the main components of the drug is microbiological fermented pollen powder. It consists of a water-soluble fraction containing 60 mg of pollen components per tablet, and a fat-soluble fraction (3 mg per tablet). The drug also contains additional substances such as cellulose, magnesium stearate and silicon dioxide. Dosage form - tablets. Cernilton is prescribed in the complex treatment of acute and chronic prostatitis (prostatitis), as well as in the treatment of benign prostatic hyperplasia. In the latter case, the drug is used in combination with other drugs such as antibiotics